Parallax Volatility Advisers
VKTX icon

Parallax Volatility Advisers’s Viking Therapeutics VKTX Stock Holding History

Parallax Volatility Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-116,800
Closed -$3.1M – 1834
2025
Q2 		$3.1M Sell
116,800
-66,600
-36% -$1.75M 0.01% 754
2025
Q1 		$4.43M Sell
183,400
-157,300
-46% -$4.97M 0.01% 647
2024
Q4 		$13.7M Buy
340,700
+226,100
+197% +$12.9M 0.03% 460
2024
Q3 		$7.26M Buy
+114,600
New +$6.72M 0.01% 662
2023
Q2 		– Sell
-18,700
Closed -$311K – 2895
2023
Q1 		$311K Buy
+18,700
New +$193K ﹤0.01% 1871
2020
Q1 		– Sell
-44,000
Closed -$353K – 2751
2019
Q4 		$353K Hold
44,000
– – ﹤0.01% 1859
2019
Q3 		$303K Hold
44,000
– – ﹤0.01% 1749
2019
Q2 		$365K Hold
44,000
– – ﹤0.01% 1585
2019
Q1 		$437K Hold
44,000
– – ﹤0.01% 1588
2018
Q4 		$337K Buy
+44,000
New +$526K ﹤0.01% 1608

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallax Volatility Advisers's VKTX Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 35,540 shares — an estimated $942K sold.

Parallax Volatility Advisers first reported a position in VKTX in Q4 2017 and held it in 14 quarters. The position peaked at $10.8M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 35,540 Viking Therapeutics shares in Q3 2025, an estimated $942K.
  • Parallax Volatility Advisers first reported a position in Viking Therapeutics in Q4 2017 and held it in 14 quarters.
  • Parallax Volatility Advisers's Viking Therapeutics position peaked at $10.8M in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.